ARTL — ARTELO BIOSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1621221 ·
Last close
$0.77
Market Cap
$2.68M
52W High
$3.57
52W Low
$0.70
ADV30
231,600
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,689,000 | -2,958,000 | 12,518,000 | 10,273,000 | 5,846,000 |
| Dec 2025 | 0 | — | -2,786,000 | -4,166,000 | 2,801,000 | 600,000 | 4,073,000 |
| Sep 2025 | 0 | — | -3,089,000 | -3,120,000 | 4,267,000 | 1,720,000 | 4,900,000 |
| Jun 2025 | 0 | — | -3,150,000 | -3,221,000 | 4,357,000 | 2,066,000 | 5,763,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,114,000
Investing CF
$-62,000
Financing CF
$17,727,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-45.29
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-65,973,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-13,064,000
Pretax Income TTM
$-13,465,000
Interest Exp TTM
$401,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,404,000 | -12,879,000 | 2,801,000 | 4,073,000 | — | -8,520,000 |
| Dec 2024 | 0 | -10,108,000 | -9,826,000 | 4,698,000 | 1,841,000 | — | -8,350,000 |
| Dec 2023 | 0 | -9,930,000 | -9,289,000 | 13,043,000 | 1,291,000 | — | -8,207,000 |
| Dec 2022 | 0 | -10,287,000 | -10,083,000 | 20,424,000 | 1,021,000 | — | -8,008,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.88
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CASIF | CASI Pharmaceuticals, Inc. | $2.67M | $0.13 | — |
| SBFM | Sunshine Biopharma Inc. | $2.78M | $1.17 | — |
| MBRX | Moleculin Biotech, Inc. | $2.83M | $0.40 | — |
| CMND | Clearmind Medicine Inc. | $2.51M | $1.69 | — |
| BIXT | BIOXYTRAN, INC | $2.49M | $0.02 | — |
News headlines (Yahoo Finance, 1h cache)
New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
2026-07-22 12:39 · Yahoo
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
2026-07-16 12:48 · Yahoo
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
2026-07-14 12:47 · Yahoo
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
2026-07-13 13:02 · Yahoo
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
2026-07-01 12:42 · Yahoo
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026
2026-06-30 12:57 · Yahoo
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026
2026-06-29 12:45 · Yahoo
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
2026-06-10 11:38 · Yahoo
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
2026-05-14 20:05 · Yahoo
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development
2026-04-28 12:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.